Novel Therapeutics for Urological Cancers

3,956
Total downloads
15k
Total views and downloads

Articles

ORIGINAL RESEARCH

Accepted on 21 Oct 2025

Nobiletin mitigates benign prostatic hyperplasia by suppressing prostate cell proliferation through regulation of cell cycle progression, signaling pathways, transcription factor activity, and the androgen-signaling axis

Jun-Hui Song
Daeun Lee
Byungdoo Hwang
Seon-Kyung Hwang
Sumin Choo
Hyeon Ji Jeong
Hoon Kim
Seok-Joong Yun
Yung Hyun Choi
1 more
Sung-Kwon Moon

doi 10.3389/fphar.2025.1661201

ORIGINAL RESEARCH

Published on 15 Aug 2025

Therapeutic outcomes of enzalutamide-docetaxel combination versus docetaxel monotherapy in post-sequential androgen receptor axis-targeted therapy failure metastatic castration-resistant prostate cancer

Zhiyu Zhang
Yanhang Yu
Chuanao Zhang
Jianglei Zhang
Xuefeng Zhang
Jun Ouyang

doi 10.3389/fonc.2025.1608786

1,142 views

REVIEW

Published on 17 Mar 2025

Adjunctive techniques for renal cell carcinoma ablation: an update

Tiago Paulino Torres
Ioanis Liakopoulos
Vasilios Balomenos
Stavros Grigoriadis
Olympia Papakonstantinou
Nikolaos Kelekis
Dimitrios Filippiadis

doi 10.3389/fradi.2025.1559411

2,249 views
2 citations

ORIGINAL RESEARCH

Published on 11 Mar 2025

Gut microbiota-derived metabolite phenylacetylglutamine inhibits the progression of prostate cancer by suppressing the Wnt/β-catenin signaling pathway

Jing Lv
Shengkai Jin
Yuhua Zhou
Chaowei Fu
Yang Shen
Bo Liu
Jufa Li
Menglu Li
Yuwei Zhang
Ninghan Feng

doi 10.3389/fphar.2025.1528058

2,495 views
3 citations

ORIGINAL RESEARCH

Published on 24 Feb 2025

Cepharanthine hydrochloride: a novel ferroptosis-inducing agent for prostate cancer treatment

Jing-Song Guan
Jing Jia
Ze-Xiu Huang
Yu-Qing Zhou
Jing-Jie Zheng
Qi-Man Lin
Yi-Fei Wang
Jiang-Lin Fan
Yao Wang

doi 10.3389/fphar.2025.1536375

2,151 views
2 citations

CASE REPORT

Published on 06 Feb 2025

Bladder-sparing therapy in a case report of huge muscle-invasive bladder IMT treated with 1470 nm diode laser en bloc resection followed by laparoscopic partial cystectomy

Junhao Chu
Huisheng Yuan
Zhihui Zhang
Jiajun Kan
Shishuai Duan
Zilong Wang
Muwen Wang

doi 10.3389/fonc.2025.1519676

1,002 views

ORIGINAL RESEARCH

Published on 09 Jan 2025

Gut microbiota derived metabolite trimethylamine N-oxide influences prostate cancer progression via the p38/HMOX1 pathway

Yuhua Zhou
Jing Lv
Shengkai Jin
Chaowei Fu
Bo Liu
Yang Shen
Menglu Li
Yuwei Zhang
Ninghan Feng

doi 10.3389/fphar.2024.1526051

2,348 views
4 citations

Share on

Frontiers in Pharmacology

Pharmacology of Anti-Cancer Drugs

Participating Journals

Frontiers in Oncology
- Pharmacology of Anti-Cancer Drugs
- 3.3 impact factor
- 6.9 citescore

Impact

15kTopic views
10kArticle views
3,956Article downloads

View impact

Articles

Nobiletin mitigates benign prostatic hyperplasia by suppressing prostate cell proliferation through regulation of cell cycle progression, signaling pathways, transcription factor activity, and the androgen-signaling axis

Therapeutic outcomes of enzalutamide-docetaxel combination versus docetaxel monotherapy in post-sequential androgen receptor axis-targeted therapy failure metastatic castration-resistant prostate cancer

Adjunctive techniques for renal cell carcinoma ablation: an update

Gut microbiota-derived metabolite phenylacetylglutamine inhibits the progression of prostate cancer by suppressing the Wnt/β-catenin signaling pathway

Cepharanthine hydrochloride: a novel ferroptosis-inducing agent for prostate cancer treatment

Bladder-sparing therapy in a case report of huge muscle-invasive bladder IMT treated with 1470 nm diode laser en bloc resection followed by laparoscopic partial cystectomy

Gut microbiota derived metabolite trimethylamine N-oxide influences prostate cancer progression via the p38/HMOX1 pathway

Frontiers in Pharmacology

Pharmacology of Anti-Cancer Drugs

Participating Journals

Frontiers in Oncology

Pharmacology of Anti-Cancer Drugs